Document Type : Original Research


1 Department of Pathology, Namazi Teaching Hospital, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

2 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran



Background & Objective: Colorectal cancer is the second reason for cancer-associated death. The prognosis of the malignancy is defined by TNM scoring. However, tumor grading, lymphovascular invasion, perineural invasion, and tumor buddings may affect its prognosis. This study aimed to assess the prognostic and histologic impact of tumor budding in colorectal adenocarcinoma.
Methods: This study is a retrospective cohort of 192 patients with colorectal adenocarcinoma. All four stages of colorectal adenocarcinoma patients were included, but the patients in stages I and II were also analyzed separately. We used pathology reports to extract the histopathologic data. The prognostic values were extracted by calling the patients.
Results: Less than half of the patients were in stages I and II of the disease. According to our analysis, tumor extension and lymphovascular invasion were correlated with tumor budding count in patients in stages I and II, and lymphovascular invasion, tumor grade, tumor stage, lymph node involvement, tumor extension, tumor site, metastasis, and five-year survival were correlated with tumor budding within all stages.
Conclusion: It is recommended that tumor budding count should be assessed and reported in pathology reports of adenocarcinomas due to its high correlation with poor prognosis.


Main Subjects

  1. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174. [DOI:10.1016/j.tranon.2021.101174] [PMID]
  2. Lugli A, Karamitopoulou E, Zlobec I. Tumor budding: a promising parameter in colorectal cancer. Br J Cancer. 2012;106(11):1713-7. [DOI:10.1038/bjc.2012.127] [PMID]
  3. Koelzer VH, Assarzadegan N, Dawson H, Mitrovic B, Grin A, Messenger DE, et al. Cytokeratin‐based assessment of tumor budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience. J pathol Clin Res. 2017;3(3):171-8. [DOI:10.1002/cjp2.73] [PMID]
  4. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180-4. [DOI:10.1093/jnci/dji237] [PMID]
  5. Loughrey MB, Quirke P, Shepherd NA. Standards and datasets for reporting cancers Dataset for histopathological reporting of colorectal cancer September 2018. Avialable at: https://www rcpath org/resourceLibrary/g049-dataset-for-histopathological-reporting-of-colorectalcancer html [accessed January 30, 2019]. 2018.
  6. Prall F. Tumor budding in colorectal carcinoma. Histopathology. 2007;50(1):151-62. [DOI:10.1111/j.1365-2559.2006.02551.x] [PMID]
  7. De Smedt L, Palmans S, Sagaert X. Tumor budding in colorectal cancer: what do we know and what can we do? Virchows Arch. 2016;468(4):397-408. [DOI:10.1007/s00428-015-1886-5] [PMID]
  8. Borley N, Wheeler J. Management of early rectal cancer. Br J Surg. 2008;95(9):1189-90. [DOI:10.1002/bjs.6372] [PMID]
  9. Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127(2):385-94. [DOI:10.1053/j.gastro.2004.04.022] [PMID]
  10. Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299-311. [DOI:10.1038/modpathol.2017.46] [PMID]
  11. Edge SB. AJCC cancer staging manual. Springer. 2010;7:97-100.
  12. Bektaş SS, Mamak GI, Çırış İM, Bozkurt KK, Kapucuoğlu N. Tumor budding in colorectal carcinomas. Turk J Patho. 2012;28(1):061-6. [DOI:10.5146/tjpath.2012.01099] [PMID]
  13. Mehta A, Goswami M, Sinha R, Dogra A. Histopathological Significance and Prognostic Impact of Tumor Budding in Colorectal Cancer. Asian Pac J Cancer Prev. 2018;19(9):2447-53.
  14. Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, et al. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol. 2010;16(38):4823. [DOI:10.3748/wjg.v16.i38.4823] [PMID]
  15. Lai YH, Wu LC, Li PS, Wu WH, Yang SB, Xia P, et al. Tumor budding is a reproducible index for risk stratification of patients with S tage II colon cancer. Colorectal Dis. 2014;16(4):259-64. [DOI:10.1111/codi.12454] [PMID]
  16. Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008;51(5):568-72. [DOI:10.1007/s10350-008-9192-9] [PMID]
  17. Graham RP, Vierkant RA, Tillmans LS, Wang AH, Laird PW, Weisenberger DJ, et al. Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort. Am J Surg Pathol. 2015;39(10):1340-6. [DOI:10.1097/PAS.0000000000000504] [PMID] []
  18. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33(1):134-41. [DOI:10.1097/PAS.0b013e318184cd55] [PMID]
  19. Horcic M, Koelzer VH, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44(5):697-705. [DOI:10.1016/j.humpath.2012.07.026] [PMID]
  20. Jagadale K, Agarwal N. Tumor budding is a predictor of lymph node metastasis in colorectal carcinoma. Int J Clin Diagn Pathol. 2020;3(1):299-301. [DOI:10.33545/pathol.2020.v3.i1e.188]
  21. Guzińska-Ustymowicz K. The role of tumor budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res. 2005;25(2B):1269-72.
  22. Ohtsuki K, Koyama F, Tamura T, Enomoto Y, Fujii H, Mukogawa T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28(3B): 1831-6.
  23. Tanaka M, Yojiro Hashiguchi MDHUMDKHMDHMMD. Tumor Budding at the Invasive Margin Can Predict Patients at High Risk of Recurrence After Curative Surgery for Stage II, T3 Colon Cancer. Dis Colon Rectum. 2003;46(8):1054-9. [DOI:10.1007/s10350-004-7280-z] [PMID]
  24. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepato-gastroenterology. 2005;52(65):1432-5.
  25. Suzuki A, Togashi K, Nokubi M, Koinuma K, Miyakura Y, Horie H, et al. Evaluation of venous invasion by Elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol. 2009;33(11):1601-7. [DOI:10.1097/PAS.0b013e3181ae29d6] [PMID]
  26. Mitrovic B, Handley K, Assarzadegan N, Chang HL, Dawson HA, Grin A, et al. Prognostic and predictive value of tumor budding in colorectal cancer. Clin Colorectal Cancer. 2021;20(3):256-64. [DOI:10.1016/j.clcc.2021.05.003] [PMID]
  27. Rogers AC, Gibbons D, Hanly AM, Hyland JMP, O'Connell PR, Winter DC, et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2014;27(1): 156-62. [DOI:10.1038/modpathol.2013.124] [PMID]
  28. Petrelli F, Pezzica E, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, et al. Tumor budding and survival in stage II colorectal cancer: a systematic review and pooled analysis. J Gastrointest Cancer. 2015; 46(3):212-8. [DOI:10.1007/s12029-015-9716-1] [PMID]
  29. Betge J, Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Onc. 2012;19(12):3706-12. [DOI:10.1245/s10434-012-2426-z] [PMID]
  30. Ryan É, Khaw YL, Creavin B, Geraghty R, Ryan EJ, Gibbons D, et al. Tumor budding and PDC grade are stage independent predictors of clinical outcome in mismatch repair deficient colorectal cancer. Am J surgical Pathol. 2018;42(1):60-8. [DOI:10.1097/PAS.0000000000000931] [PMID]